Physician profile
Sandy Oh
NPI 1851325203
$7,111.73
in general payments reported to CMS, 2019-2025
42 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $673 · 2021: $875 · 2022: $876 · 2023: $1,472 · 2024: $1,120 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867 · Education: $30.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.54 |
| Education | $30.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,027.89 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $669.33 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $592.10 | 2020-2025 | |
| Lilly USA, LLC | $547.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.85 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $420.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $353.20 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $350.79 | 2019-2025 | |
| Pfizer INC. | $330.87 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $283.46 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $218.34 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $205.55 | 2023-2025 | Rexulti, Nuedexta |
| Phathom Pharmaceuticals, INC. | $204.15 | 2024-2025 | Voquezna |
| Lexicon Pharmaceuticals, INC. | $124.12 | 2024 | |
| Amarin Pharma, INC. | $106.34 | 2020-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $98.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $94.51 | 2019-2021 | |
| Allergan, INC. | $86.43 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.25 | 2025 | |
| Sumitomo Pharma America, INC. | $81.30 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $75.83 | 2024-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $63.17 | 2019-2022 | |
| Biogen, INC. | $62.89 | 2021-2022 | |
| Axsome Therapeutics, INC. | $55.03 | 2025 | Symbravo |
| Esperion Therapeutics, INC. | $49.77 | 2020-2021 | |
| Bio Products Laboratory USA, INC. | $43.72 | 2023 | Coagadex, Gammaplex |
| Merck Sharp & Dohme LLC | $42.43 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $40.80 | 2022-2023 | Rayaldee |
| Amneal Pharmaceuticals LLC | $36.04 | 2021 | |
| Corium, LLC | $34.03 | 2023 | Adlarity |
| Ibsa Pharma INC. | $31.45 | 2020-2025 | Tirosint, Flector, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.64 | 2024-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $29.28 | 2019-2020 | |
| Orexo US, INC. | $27.00 | 2020-2021 | |
| Lundbeck LLC | $26.99 | 2023-2025 | Rexulti |
| Harmony Biosciences LLC | $25.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.87 | 2022 | |
| Vivus LLC | $18.81 | 2019 | |
| Eisai INC. | $17.67 | 2019 | |
| Alfasigma USA, INC. | $16.74 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.41 | 2020 | |
| Melinta Therapeutics, LLC | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.